Gene therapy restores hearing in children with deafness

Gene therapy restores hearing in deaf children

July 12, 2025

news

By Alice Carliez THE Subscribers

In early July 2025, two competing teams, one French and one Chinese, published the first results—positive and encouraging—from their clinical trials of gene therapy to treat DFNB9 deafness. The ultimate goal: to restore natural hearing for patients suffering from this neuropathy.

Read moreCovid-19 management: three former government members, including Edouard Philippe, expected to be dismissed on Monday

Gene therapy to treat deafness

Solution for different hair types
Read moreSolution for different hair types

The gene therapies developed by the various laboratories all aim to restore complete hearing to patients suffering from DFNB9 neuropathy.

Pixabay / Pexels / Alice Carliez

In France and China, there is good news regarding gene therapy to restore hearing. This concerns the genetic neuropathy DFNB9, which accounts for approximately 5% of cases of deafness at birth, according to the Hearing Foundation.

The first results of the clinical trial, conducted by the Karolinska Institutet in Stockholm, Sweden, the Otovia industry and several university hospitals in China, were published on July 2, 2025, in the journal Nature Medicine. On the French side, the 1er July, Sensorion announces in a press release preliminary data from Audiogene, the first clinical trial of SENS-501 gene therapy, led by the Institut Pasteur and Necker-Enfants Malades Hospital (Paris).

Hearing Deafness Gene therapy Genetic Children Genetic disease

“
»
en_USEnglish
fr_FRFrench en_USEnglish